Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M
Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program
Additionally, the US FDA has also approved Wegovy and Rybelsus to help reduce cardiovascular risks in high-risk patients who also have obesity
doi: 10.1371/journal.pone.0238289 18 Fernndez
Working with your healthcare provider to navigate insurance coverage, or exploring compounded options for affordable access, can make these medications achievable for most patients who would benefit
Weekly Injections & Follow-Ups You receive weekly Semaglutide or Tirzepatide at our Santa Ana clinic, with monthly appointments for weight tracking, medication adjustments, and lab monitoring